Semin Plast Surg 2010; 24(2): 127-136
DOI: 10.1055/s-0030-1255330
© Thieme Medical Publishers

Radiotherapy for Head and Neck Cancer

Shyh-An Yeh1
  • 1Department of Radiation Oncology, E-Da Hospital, Kaohsiung, Taiwan
Further Information

Publication History

Publication Date:
21 June 2010 (online)

ABSTRACT

Treatment for patients with head and neck cancer requires a multidisciplinary approach. Radiotherapy is employed as a primary treatment or as an adjuvant to surgery. Each specific subsite dictates the appropriate radiotherapy techniques, fields, dose, and fractionation scheme. Quality of life is also an important issue in the management of head and neck cancer. The radiation-related complications have a tremendous impact on the quality of life. Modern radiotherapy techniques, such as intensity-modulated radiotherapy and image-guided radiotherapy, can offer precise radiation delivery and reduce the dose to the surrounding normal tissues without compromise of target coverage. In the future, efforts should be made in the exploration of novel strategies to improve treatment outcome in patients with head and neck cancer.

REFERENCES

  • 1 Kies M S, Haraf D J, Athanasiadis I et al.. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.  J Clin Oncol. 1998;  16 2715-2721
  • 2 Vokes E E, Kies M S, Haraf D J et al.. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.  J Clin Oncol. 2000;  18 1652-1661
  • 3 Fu K K, Pajak T F, Trotti A et al.. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.  Int J Radiat Oncol Biol Phys. 2000;  48 7-16
  • 4 Olmi P, Crispino S, Fallai C et al.. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial.  Int J Radiat Oncol Biol Phys. 2003;  55 78-92
  • 5 El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials.  J Clin Oncol. 1996;  14 838-847
  • 6 Pignon J P, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.  Lancet. 2000;  355 949-955
  • 7 Katz T S, Mendenhall W M, Morris C G, Amdur R J, Hinerman R W, Villaret D B. Malignant tumors of the nasal cavity and paranasal sinuses.  Head Neck. 2002;  24 821-829
  • 8 Chobe R, McNeese M, Weber R, Fletcher G H. Radiation therapy for carcinoma of the nasal vestibule.  Otolaryngol Head Neck Surg. 1988;  98 67-71
  • 9 Lee N, Phillips T L. Cancer of the oral cavity. In: Leibel SA, Phillips TL Textbook of Radiation Oncology. Philadelphia, PA; Saunders 2004: 631-655
  • 10 Al-Sarraf M, Leblanc M, Giri P G et al.. Superiority of five year survival with chemo-radiotherapy vs. radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III Study: Final Report.  Proc Am Soc Clin Oncol. 2001;  20 227a
  • 11 Levendag P C, Lagerwaard F J, Noever I et al.. Role of endocavitary brachytherapy with or without chemotherapy in cancer of the nasopharynx.  Int J Radiat Oncol Biol Phys. 2002;  52 755-768
  • 12 Choy D, Sham J S, Wei W I, Ho C M, Wu P M. Transpalatal insertion of radioactive gold grain for the treatment of persistent and recurrent nasopharyngeal carcinoma.  Int J Radiat Oncol Biol Phys. 1993;  25 505-512
  • 13 Syed A M, Puthawala A A, Damore S J et al.. Brachytherapy for primary and recurrent nasopharyngeal carcinoma: 20 years' experience at Long Beach Memorial.  Int J Radiat Oncol Biol Phys. 2000;  47 1311-1321
  • 14 Denis F, Garaud P, Bardet E et al.. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma.  J Clin Oncol. 2004;  22 69-76
  • 15 Mendenhall W M, Amdur R J, Stringer S P, Villaret D B, Cassisi N J. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery?.  J Clin Oncol. 2000;  18 2219-2225
  • 16 Zelefsky M J, Harrison L B, Armstrong J G. Long-term treatment results of postoperative radiation therapy for advanced stage oropharyngeal carcinoma.  Cancer. 1992;  70 2388-2395
  • 17 Hu K S, Harrison L B, Culliney B et al.. Cancer of the oropharynx. In: Leibel SA, Phillips TL Textbook of Radiation Oncology. Philadelphia, PA; Saunders 2004: 601-630
  • 18 Zelefsky M J. Cancer of the hypopharynx. In: Leibel SA, Phillips TL Textbook of Radiation Oncology. Philadelphia, PA; Saunders 2004: 657-678
  • 19 Lefebvre J L, Chevalier D, Luboinski B et al.. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial.  J Clin Oncol. 2004;  22(Suppl 14) 5531
  • 20 Ton-Van J, Lefebvre J L, Stern J C, Buisset E, Coche-Dequeant B, Vankemmel B. Comparison of surgery and radiotherapy in T1 and T2 glottic carcinomas.  Am J Surg. 1991;  162 337-340
  • 21 Morris M R, Canonico D, Blank C. A critical review of radiotherapy in the management of T1 glottic carcinoma.  Am J Otolaryngol. 1994;  15 276-280
  • 22 Mendenhall W M, Amdur R J, Morris C G, Hinerman R W. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy.  J Clin Oncol. 2001;  19 4029-4036
  • 23 Fein D A, Mendenhall W M, Parsons J T, Million R R. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control.  Int J Radiat Oncol Biol Phys. 1993;  25 605-611
  • 24 Carl J, Andersen L J, Pedersen M, Greisen O. Prognostic factors of local control after radiotherapy in T1 glottic and supraglottic carcinoma of the larynx.  Radiother Oncol. 1996;  39 229-233
  • 25 Klintenberg C, Lundgren J, Adell G et al.. Primary radiotherapy of T1 and T2 glottic carcinoma—analysis of treatment results and prognostic factors in 223 patients.  Acta Oncol. 1996;  35(Suppl 8) 81-86
  • 26 Armstrong J G, Harrison L B, Spiro R H, Fass D E, Strong E W, Fuks Z Y. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy.  Arch Otolaryngol Head Neck Surg. 1990;  116 290-293
  • 27 Eisbruch A, Ten Haken R K, Kim H M, Marsh L H, Ship J A. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer.  Int J Radiat Oncol Biol Phys. 1999;  45 577-587
  • 28 Nutting C, Dearnaley D P, Webb S. Intensity modulated radiation therapy: a clinical review.  Br J Radiol. 2000;  73 459-469
  • 29 Mell L K, Roeske J C, Mundt A J. A survey of intensity-modulated radiation therapy use in the United States.  Cancer. 2003;  98 204-211
  • 30 Cummings B, O'Sullivan B, Keane T et al.. 5-year results of a 4 weeks/twice daily radiation schedule. The Toronto Trial.  Radiother Oncol. 2000;  56(Suppl 1) S8
  • 31 Skladowski K, Maciejewski B, Golen M, Pilecki B, Przeorek W, Tarnawski R. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity.  Radiother Oncol. 2000;  55 101-110
  • 32 Fu K K, Clery M, Ang K K, Byhardt R W, Maor M H, Beitler J J. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.  Int J Radiat Oncol Biol Phys. 1995;  32 589-597
  • 33 Lee N, Xia P, Quivey J M et al.. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience.  Int J Radiat Oncol Biol Phys. 2002;  53 12-22
  • 34 Chong L M, Armstrong J G. Tumors of the salivary glands. In: Leibel SA, Phillips TL Textbook of Radiation Oncology. Philadelphia, PA; Saunders 2004: 699-729
  • 35 Mossman K, Shatzman A, Chencharick J. Long-term effects of radiotherapy on taste and salivary function in man.  Int J Radiat Oncol Biol Phys. 1982;  8 991-997
  • 36 Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow-up study 7 to 11 years after radiotherapy.  Int J Radiat Oncol Biol Phys. 1994;  28 847-856
  • 37 Brizel D M, Wasserman T H, Henke M et al.. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.  J Clin Oncol. 2000;  18 3339-3345
  • 38 Lindegaard J C, Grau C. Has the outlook improved for amifostine as a clinical radioprotector?.  Radiother Oncol. 2000;  57 113-118
  • 39 Blom M, Dawidson I, Fernberg J O, Johnson G, Angmar-Månsson B. Acupuncture treatment of patients with radiation-induced xerostomia.  Eur J Cancer B Oral Oncol. 1996;  32B 182-190
  • 40 LeVeque F G, Montgomery M, Potter D et al.. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients.  J Clin Oncol. 1993;  11 1124-1131
  • 41 Jha N, Seikaly H, Harris J et al.. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space.  Radiother Oncol. 2003;  66 283-289
  • 42 Myers R A, Marx R E. Use of hyperbaric oxygen in postradiation head and neck surgery.  NCI Monogr. 1990;  9 151-157
  • 43 Lee A W, Law S C, Ng S H et al.. Retrospective analysis of nasopharyngeal carcinoma treated during 1976-1985: late complications following megavoltage irradiation.  Br J Radiol. 1992;  65 918-928
  • 44 Lee N, Phillips T L. Cancer of the larynx. In: Leibel SA, Phillips TL Textbook of Radiation Oncology. Philadelphia, PA; Saunders 2004: 679-698
  • 45 Grau C, Møller K, Overgaard M, Overgaard J, Elbrønd O. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma.  Int J Radiat Oncol Biol Phys. 1991;  21 723-728
  • 46 Kwong D L, Wei W I, Sham J S et al.. Sensorineural hearing loss in patients treated for nasopharyngeal carcinoma: a prospective study of the effect of radiation and cisplatin treatment.  Int J Radiat Oncol Biol Phys. 1996;  36 281-289
  • 47 Parsons J T, Fitzgerald C R, Hood C I, Ellingwood K E, Bova F J, Million R R. The effects of irradiation on the eye and optic nerve.  Int J Radiat Oncol Biol Phys. 1983;  9 609-622
  • 48 Emami B, Lyman J, Brown A et al.. Tolerance of normal tissue to therapeutic irradiation.  Int J Radiat Oncol Biol Phys. 1991;  21 109-122
  • 49 McCaffrey T V, Fisher J. Effect of radiotherapy on the outcome of pharyngeal reconstruction using free jejunal transfer.  Ann Otol Rhinol Laryngol. 1987;  96(1 Pt 1) 22-25
  • 50 Cole C J, Garden A S, Frankenthaler R A et al.. Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck.  Cancer. 1995;  75 2356-2360

Shyh-An YehM.D. 

Department of Radiation Oncology, E-Da Hospital, No. 1, E-Da Road, Yan-Chau Shiang, Kaohsiung County

Taiwan 82445

Email: yehsa@hotmail.com

    >